Meet Our Team
Todd C. Davis has more than 30 years of operational and investment experience in the pharmaceutical and life science industries. He has led over $3 billion in healthcare deals including growth equity, structured debt and royalty acquisitions throughout his career. Mr. Davis has also led, structured and closed more than 40 intellectual property licenses, as well as hybrid royalty-debt deals. Prior to Benuvia, he held senior leadership roles at RoyaltyRx Capital, Healthcare Royalty Partners and Apax Partners. Previously, he held general management, business development, and licensing roles at Elan Pharmaceuticals and commercial and operational roles at Abbott Laboratories.
Mr. Davis is a Navy veteran, holds an MBA from Harvard University, and a BS from the U.S. Naval Academy. He currently serves on the board of BioDelivery Sciences International, Ligand Pharmaceuticals and Palvella Therapeutics.
Scott Aladeen has held a broad range of positions in the Pharmaceutical Industry over the past four decades. His career has included executive leadership, operations management, quality assurance & control, manufacturing, supply chain and product development. Scott has led or been a part of the leadership team at firms engaged in branded pharmaceuticals, generic drugs, CDMO services and most recently outsource sterile drug compounding (503b pharmacy services). He has been a part of large, diverse domestic and international companies including Boehringer Ingelheim, Sanofi, Astellas, and AmerisourceBergen (ABC) as well as smaller companies such as Avara and QuVa Pharma. His positions have included EVP, COO and President.
Scott started as a bench chemist developing analytical methods for new drug products. He worked his way through the quality control and quality assurance organizations, eventually leading those functions before moving into operations management. In operations, Scott has led production facility design, startup and operation and taken responsibility for an entire supply chain across the Americas for products with revenues exceeding $1.5 billion. Scott has overseen manufacturing division divestiture and transformed the newly formed company into a full-service, successful CDMO. He has led during explosive growth, and steered through consent decree remediation.
Scott Warlick has more than 25 years of experience leading chemical and pharmaceutical operations. Over the course of his career, Mr. Warlick has led operations in bulk API, specialty API, orals solid dose, and drug delivery systems. As VP, Manufacturing, he is responsible for Benuvia’s Texas manufacturing site overseeing the production of commercial active pharmaceutical ingredients (API) and registration batches for new drug applications. Prior to joining Benuvia, Mr. Warlick served as Senior Director of Manufacturing at Mylan where he led the granulation department (blending, roller compaction, and fluid bed granulation). Previously, Mr. Warlick served in numerous capital management and process improvement roles at Mallinckrodt including site lead at the company’s 200-employee bulk acetaminophen API site. Mr. Warlick received an MBA from Duke University and a BS in Chemical Engineering from North Carolina State University.
James Doroz has over 25 years of experience leading financial teams in various industries, including manufacturing, pharmaceuticals, natural resources and software. As VP of Finance and Controller, Mr. Doroz is responsible for Benuvia Manufacturing’s financial controls and for financial planning and analysis. Prior to joining Benuvia, Mr. Doroz was the Director of Finance at Adaptive Curriculum, a web based company devoted to helping students succeed in math and science mastery. Prior to his work at Adaptive Curriculum, he served at iGo. He has served in various financial roles with Sanmina and BHP Billiton.
Mr. Doroz received a BS in Accounting and Finance from the University of Arizona.
Monica Gorbet has more than 25 years of experience in pharmaceutical operations with expertise in quality systems, quality assurance, compliance, and quality control. As Director, Quality Assurance, she leads quality activities including compliance of regulatory requirements associated with manufacturing and development at Benuvia’s Texas site. Prior to joining Benuvia, she served as the Director of Quality Assurance for PharmaForm, a midsize contract development manufacturing organization where she successfully led the company through numerous regulatory and customer site inspections. Previously, Ms. Gorbet served in various quality roles at Astellas Pharma Technologies, Pfizer, Aventis-Behring (now CSL Behring) and Hoechst Celanese. Ms. Gorbet received a BS in Biology from Texas A&M – Kingsville.
Brandon Kidd has more than 20 years of investment and operational experience with deep experience in the cannabidiol industry. As the VP for Business Development, Mr. Kidd is responsible for new client relationships, joint ventures and strategic partnerships, as well as domestic and international sales. He previously served as a Managing Director at Mile High Labs, the global leader in industrial scale cannabidiol ingredient manufacturing. Prior to Mile High Labs, Mr. Kidd served as Managing Partner at Green Capital, a private investment firm focused on the cannabis industry. Earlier in his career, Mr. Kidd served as a strategic advisor to leading private equity and real estate firms including Kimco Realty Corporation.
Mr. Kidd received a BA in International Relations from the University of Colorado Boulder. He is fluent in Portuguese and Spanish.
Karon J. Morell’s professional career spans over 50 years with 27 of them in executive leadership roles in the biotech, tissue, medical and pharmaceutical industries. Ms. Morell has deep compliance, clinical, regulatory, quality affairs, manufacturing, and technical operational expertise. Over the course of her career, she has successfully led diverse teams globally, achieved international agency product and facility approvals and has never received a U.S. FDA or International FDA inspection observation or finding.
Prior to Benuvia, Ms. Morell held senior positions in compliance, regulatory, quality affairs and operations for Suneva Medical and its predecessor company for 12 years. During her tenure at the firm, Ms. Morell was responsible for the oversight of the company’s California corporate manufacturing facility for Artefill (now Bellafill) and its German facility which produced the critical raw component Polymethyl methacrylate (PMMA). Previously, Ms. Morell served as VP of Compliance, Regulatory, Quality Systems, Assurance & Control and as Tissue Bank Director at IsoTis Orthobiologics (now Integra LifeSciences). At IsoTis, she was instrumental in re-classifying some of the company’s biological human tissue products as medical devices. Prior to IsoTis, she held senior quality and regulatory roles at Medegen Medical Products, Nobel Biocare and Newport Medical Instruments.
Ms. Morell received a BS in Business Management from Southern California University.
Jim Mitchell has more than 20 years of experience as an organic chemist focused primarily on organic synthesis, natural products isolation, and structure elucidation with an emphasis on cannabinoid chemistry. He leads Benuvia’s research and process development group in process oversight; development and translation of new industrial cannabinoid processes; formulation and API impurity isolation and structure elucidation; in addition to custom synthesis campaigns for various cannabinoid derivatives of industrial importance. Mr. Mitchell is also responsible for the modernization of other cannabinoid scaffolds for industrial GMP production and preclinical/clinical investigations. Prior to Benuvia, he served in research and chemistry roles at several clinical research and manufacturing companies.
He received a BS in Chemistry from the University of Texas at Austin and studied organic chemistry at the University of Hawaii at Manoa.
Thrimoorthy Potta has more than 15 years of extensive product development experience in both branded and generic pharmaceuticals across a broad range of technologies and dosage forms. As VP, Research & Development, he leads all operations in the development of liquid orals, sublingual sprays, Intranasal sprays inhalation aerosols and solid dosage forms from inception to the product launch. Mr. Potta’s team has launched several drug products and handled the submission of several IND’s and NDA’s. Prior to Benuvia, Mr. Potta held R&D leadership positions at some of the most successful generic pharmaceutical companies including Sun Pharmaceutical Industries Ltd and Gland Pharma Ltd. He has authored and co-authored more than 20 peer-reviewed publications and has several patents. Mr. Potta received a Master’s in pharmaceutical chemistry and a PhD in pharmaceutics and post-doctoral research in chemical engineering from Arizona State university. He serves as an Editorial Advisory Board Member of Recent Patents on Drug Delivery & Formulation.